GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Institutional Ownership

Incanthera (AQSE:INC) Institutional Ownership : 2.75% (As of Jun. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Incanthera's institutional ownership is 2.75%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Incanthera's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Incanthera's Float Percentage Of Total Shares Outstanding is 0.00%.


Incanthera Institutional Ownership Historical Data

The historical data trend for Incanthera's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Institutional Ownership Chart

Incanthera Historical Data

The historical data trend for Incanthera can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 2.75 2.75 2.75 2.75 2.75 2.75

Incanthera Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines